H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Legend Biotech (LEGN) to $75 from $73 and keeps a Buy rating on the shares. The firm says Legend expects to meet 2025 the consensus estimate of $1.9B in Carvykti revenue as supply will outpace demand by the end of the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech’s Promising Growth Trajectory: Revenue Milestones and Strategic Initiatives Drive Future Success
- Legend Biotech’s 2024 Earnings Highlight CARVYKTI® Success
- Legend Biotech’s 2024 Financial Success and Strategic Advances
- Legend Biotech reports Q4 adjusted EPS (15c), consensus (38c)
- Legend Biotech sees cash runway into 2Q26
Questions or Comments about the article? Write to editor@tipranks.com